Induction of tolerance in a rat model of laryngeal transplantation

Akst, Lee M.; Siemionow, Maria; Dan, Olivia; Iżycki, Dariusz; Strome, Marshall

doi:10.1097/01.tp.0000100398.39169.5b

Cited by 28 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investigations in the past, aiming at improvements for laryngectomized patients and concentrating on developing an artificial larynx 11 and laryngeal transplantation, 34,35 have not yet led to a sustainable or long-term solution. Therefore, the development of shunt valves made of biofilm-resistant material is currently at the focus of efforts to improve the quality of life for laryngectomized patients.…”

Section: Discussionmentioning

confidence: 98%

Experimental results of the tracheoesophageal tissue connector for improved fixation of shunt valves in laryngectomized patients

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Experimental results of the tracheoesophageal tissue connector for improved fixation of shunt valves in laryngectomized patients

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Alternatively, a tolerance-inducing strategy could inactivate T cells without causing their death (anergy), generate regulatory cells that block T-cell activation and function (suppression) or induce the differentiation of naive T cells into a nonharmful phenotype (immune deviation). Moreover, immunomodulatory agents that do not consistently induce donor-specific tolerance invariably fail to suppress immunologic memory in experimental animals [20,21]. CD8 + memory T cells seem to be as susceptible to tolerance as their naive counterparts [22].…”

Section: Memory T Cellsmentioning

confidence: 95%

Developing Immunologic Tolerance for Transplantation at the Fetal Stage

Mendieta-Zerón¹

2011

Immunotherapy

View full text Add to dashboard Cite

Given the shortage of human organs for transplantation, the waiting lists are increasing annually and consequently so is the time and deaths during the wait. As most immune suppression therapy is not antigen specific and the risk of infection tends to increase, scientists are looking for new options for immunosuppression or immunotolerance. Tolerance induction would avoid the complications caused by immunosupressive drugs. As such, taking into account the experience with autoimmune diseases, one strategy could be immune modulation-induced changes in T-cell cytokine secretion or antigen therapy; however, most clinical trials have failed. Gene transfer of MHC genes across species may be used to induce tolerance to xenogenic solid organs. Other options are induction of central tolerance by the establishment of mixed chimerism through hematopoietic stem cell transplantation and the induction of 'operational tolerance' through immunodeviation involving dendritic or Tregs. I propose that, as the recognition and tolerance of proteins takes place in the thymus, this organ should be the main target for immunotolerance research protocols even as early as during the fetal development.

show abstract

“…They showed a significant dose‐response relationship between tacrolimus alone and decreasing histological rejection scores, and that the addition of MM allowed the use of low dose (0.2 mg/kg) tacrolimus without increased rejection (26). In a parallel study, a short (7‐day) course of tacrolimus combined with anti‐alpha‐beta T‐cell receptor antibody was able to prevent rejection of 10 unmatched rat laryngeal grafts for up to 100 days (27) (Figure 2A, B). Skin grafting, mixed lymphocyte reaction and flow cytometry in this study suggested that tolerance was neither donor‐specific nor related to systemic immunocompromise.…”

Section: Immunosuppression and Immunomodulationmentioning

confidence: 98%

Laryngeal Transplantation in 2005: A Review

Birchall

Lorenz

Berke

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

There is no good surgical, medical or prosthetic solution to the problems faced by those with a larynx whose function is irreversibly damaged by tumor or trauma. Over the past 10 years, the pace of research designed to establish laryngeal transplantation as a therapeutic option for these persons has increased steadily. The biggest milestone in this field was the world's first true laryngeal transplant performed in Cleveland, Ohio in 1998. The recipient's graft continues to function well, in many respects, even after 7 years. However, it has also highlighted the remaining barriers to full-scale clinical trials. Stimulated by these observations, several groups have accumulated data which point to answers to some of the outstanding questions surrounding functional reinnervation and immunomodulation. This review seeks to outline the progress achieved in this field by 2005 and to point the way forward for laryngeal transplantation research in the 21st century.

show abstract

Induction of tolerance in a rat model of laryngeal transplantation

Abstract: In this rat laryngeal-transplantation model, functional tolerance was induced under combined tacrolimus and alphabeta TCR protocol. Mechanisms responsible for this tolerance induction require future elucidation.

Cited by 28 publications

References 7 publications

Experimental results of the tracheoesophageal tissue connector for improved fixation of shunt valves in laryngectomized patients

Experimental results of the tracheoesophageal tissue connector for improved fixation of shunt valves in laryngectomized patients

Developing Immunologic Tolerance for Transplantation at the Fetal Stage

Laryngeal Transplantation in 2005: A Review

Contact Info

Product

Resources

About